

Corrections

The Problem of Rheumatoid Arthritis Disease Activity and Remission in Clinical Practice

Shaver TS, Anderson JD, Weidensaul DN, Shahouri SS, Busch RE, Mikuls TR, Michaud K, Wolfe F. The problem of rheumatoid arthritis disease activity and remission in clinical practice. *J Rheumatol* 2008;35:1015-22. The correct name of author S. Shahouri is Shadi H. Shahouri. We regret the error.

The Problem of Rheumatoid Arthritis Disease Activity and Remission in Clinical Practice

TIMOTHY S. SHAVER, JAMES D. ANDERSON, DAVID N. WEIDENSAUL, SHADI S. SHAHOURI, RUTH E. BUSCH, TED R. MIKULS, KALEB MICHAUD, and FREDERICK WOLFE

ABSTRACT. Objective. To investigate the results and feasibility of available scales to measure minimal disease activity (MDA) and remission in rheumatoid arthritis (RA) in the clinic.

Methods. We studied 849 consecutive patients with RA seen in a community rheumatology practice for routine RA care by 4 rheumatologists, beginning in March 2007 and ending in August 2007. Patients and physicians completed a simple form at each visit. We calculated the Disease Activity Score 28 (DAS28), Clinical Disease Activity Index (CDAI), physician assessment of global activity, and the Patient Activity Scale (PAS-II). From these we calculated remission and MDA prevalence in this community practice.

Results. The DAS28 could not be determined in more than 50% of patients because of referring physician and insurance company restrictions. Remission prevalences differed by assessment method: DAS28 28.5%, CDAI 6.5%–8.1%, physician global 12.5%, PAS 13.7%. MDA was 26.9% using the American College of Rheumatology core set variables, 34.7% using the DAS28, and 26.8% using the PAS-II. The kappa statistic was only fair (0.2 to 0.4) for most comparisons between assessment methods. No significant differences were noted for remission and MDA according to biologic therapy.

Conclusion. The CDAI and/or physician global and PAS-II are simple acceptable ways to measure RA activity in the clinic, but results differ strikingly according to method. Further standardization appears to be required for full implementation of the CDAI. Caution is urged before using these methods for regulatory purposes. (First Release April 15 2008; J Rheumatol 2008;35:1015–22)

Key Indexing Terms:

RHEUMATOID ARTHRITIS ASSESSMENT CLINICAL DISEASE ACTIVITY INDEX
REMISSION MINIMAL DISEASE ACTIVITY DISEASE ACTIVITY SCORE

Almost since rheumatoid arthritis (RA) was perceived to be a separate, diagnosable disorder, scales have been proposed to measure its activity, severity, and the proportion of patients in remission¹⁻¹⁶. Until recently, such scales were used by a small minority of physicians, but were the subject of extensive research interest.

In the investigation of treatment effects, disease activity is of central interest and patient symptoms often represent

“nuisance parameters.” For example, an effective treatment might result in the disappearance of RA activity, yet a patient might have pain and functional limitations from non-RA sources or consequences of RA. In addition, the severity of pain and functional limitations, even when associated with RA activity, may not be highly correlated with disease activity. However, pain, function, and other symptoms are central to patient care. In practice, physicians have to distinguish between the burden of symptoms and the measure of RA activity, and they have to deal with both.

RA activity scales generally measure joint swelling, joint tenderness, and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). In addition, they may include physician’s global, and when they contain patient measures such as patient global, the scales are still strongly weighted toward physician and laboratory measures. The assessment of patient measures, so important to clinicians and patients, usually consists of the Health Assessment Questionnaire disability index (HAQ)¹⁷ or its congeners, a pain scale, a global severity scale, or a summary measure of these such as the Patient Activity Scale (PAS)¹⁸. One can call the first

From the Arthritis and Rheumatology Clinics of Kansas; University of Kansas School of Medicine; National Data Bank for Rheumatic Diseases, Wichita, Kansas; and University of Nebraska Medical Center, Omaha, Nebraska, USA.

T.S. Shaver, MD; J.D. Anderson, MD; D.N. Weidensaul, MD; S.S. Shahouri, MD; R.E. Busch, MD, Arthritis and Rheumatology Clinics of Kansas and University of Kansas School of Medicine; T.R. Mikuls, MD, MSPH, University of Nebraska Medical Center; K. Michaud, PhD, University of Nebraska Medical Center and National Data Bank for Rheumatic Diseases; F. Wolfe, MD, National Data Bank for Rheumatic Diseases and University of Kansas School of Medicine.

Address reprint requests to Dr. F. Wolfe, National Data Bank for Rheumatic Diseases, 1035 N. Emporia, Suite 288, Wichita, KS 67214. E-mail: fwolfe@arthritis-research.org

Accepted for publication January 10, 2008.

series of measures “physician measures” and the second series “patient measures.”

Measurement has taken on a new imperative as regulators and insurance companies impose requirements on use of expensive therapies. Yet from the clinicians’ perspective, physician and patient measures may be overkill, consume valuable time, and be expensive, and may not always be available. For example, if a patient’s activity and symptoms are stable, what is to be gained by the clinician by detailed joint and laboratory examinations?

We investigated several measures of remission and disease activity that address either physician or patient measures or both. We investigated the prevalence of remission and minimal disease activity (MDA)^{4,19} in all patients and those receiving and not receiving biologics, the agreement between measures, the ability to obtain complete scales, and factors associated with scale differences.

MATERIALS AND METHODS

We studied 849 consecutive patients with RA seen in a community rheumatology practice [Arthritis and Rheumatology Clinics of Kansas (ARCK)] for routine RA care by one of 4 rheumatologists, beginning in March 2007 and ending in August 2007 (5 months). If a patient was seen more than once during the study period the most recent encounter was analyzed. Each patient was asked to complete a self-report questionnaire that consisted of the 10-item HAQ-II functional scale²⁰, a 5-category health satisfaction question, and visual analog scales (VAS) for pain, fatigue, and global severity. The reverse side of the questionnaire was completed by the rheumatologist and consisted of tender and swollen joint manikins, a medication list, a section for reporting ESR or CRP, and physician’s assessment of global disease activity. From the joint manikins we determined the 28 swollen and tender joint counts. The physician’s global question was an 11-item rating scale that was labeled as follows with respect to RA activity: 0 none, 1–3 mild, 4–7 moderate, 8–10 severe. We labeled the question this way so each physician would understand the rating scale similarly. A copy of this questionnaire can be found at www.arthritis-research.org. Study physicians used the patient questionnaires as part of their routine evaluation strategy.

Two training sessions were held with physicians and clinic staff at study startup. It was agreed that the physician’s global was to represent RA disease activity as manifested almost always by joint swelling and pain. If present, other manifestation of RA activity could be included at the discretion of the rheumatologist, including vasculitis, scleritis, etc. Clinic staff were instructed on how to keep records and how to ensure that patients and physicians completed all questions. A followup meeting 1 week later identified problem areas. This led to modifications of the study routine and questionnaire. Following completion of the questionnaires, the questionnaires were sent to the National Data Bank for Rheumatic Diseases (NDB) data center, Wichita, KS, where they were scanned into the NDB database²¹. Omissions and errors were identified immediately and immediate feedback was given to ARCK. After a few days of interaction, omissions and errors became minimal.

Remission indexes. In our study, we use the word “remission” to mean satisfying remission criteria without consideration of the duration of remission, as our purpose was to examine the level of disease activity necessary to define remission.

We calculated the Disease Activity Index 28 (DAS28) from the swollen and tender joint count, the ESR, and patient’s VAS global²². DAS28 remission was defined as a DAS28 score ≤ 2.6 ^{10,22}. We also calculated the Clinical Disease Activity Index (CDAI) by summing the swollen (0–28) and tender (0–28) joint counts, and the patient and physician global^{3,6}. A CDAI remission occurs when the CDAI score is ≤ 2.8 . In our question-

naire, as described above, physician’s global is a 0–10, 11-item rating scale. This is a modification from the original CDAI centimeter scale. This change results in slightly lower CDAI remission prevalence, and is described in the Results section. While it is not certain if this difference is important, we also calculated CDAI remission prevalence at a cutpoint of 3.0. We also defined physician or MD remission as a score ≤ 1 on the physician’s global⁴ and a PAS-II¹⁸ value of ≤ 1.25 . For comparison purposes only, we report “remission” when both swollen and tender joint counts are 0, and when swollen and tender joints are 0 and ESR ≤ 10 mm/h, as these definitions were used in minimal disease activity definitions (see immediately below).

Minimal disease activity (MDA). We calculated 3 indexes: the MDA Core Set Index was positive if the patient satisfied at least 5 of 7 of the following conditions: VAS pain (0–10) ≤ 2 , swollen joint count (0–28) ≤ 1 , tender joint count (0–28) ≤ 1 , HAQ (0–3) ≤ 0.5 , patient global severity (0–10) ≤ 2 , physician global disease activity (0–10) ≤ 1.5 , ESR ≤ 20 mm/h; OR patient satisfied the following conditions: the patient had no swollen joints, no tender joints, and an ESR ≤ 10 mm/h. The definition was called the “Core Set” definition because it made use of the published core set variables for the assessment of response in RA^{23,24}. In the second method, “DAS28 method,” patients achieved MDA status if the patient had no swollen joints, no tender joints, and an ESR ≤ 10 mm/h OR the DAS28 score was ≤ 2.85 . In the third method, PAS MDA, a patient was MDA-positive if PAS-II score was ≤ 2.2 ¹⁸. This value was modified from an original PAS value of 1.75⁴. The PAS-II is a summary measure of RA activity made by combining HAQ-II²⁵ and VAS pain and patient global scales. The range is 0–10, with higher values indicating more abnormality. The MDA Core Set and DAS28 methods were developed as part of the Outcome Measures in Rheumatology [Clinical Trials] 7 process¹⁹.

To assess the effect of methodology on remission and MDA as a function of biologic therapy, we characterized a patient as being on a biologic if he was receiving infliximab, etanercept, adalimumab, anakinra, abatacept, or rituximab.

Statistics. We separately assessed agreement between both remission and MDA indices by the kappa statistic. Fleiss indicates the interpretation of the kappa statistic in terms of strength of agreement as < 0.00 poor, > 0.00 – 0.20 slight, 0.21 – 0.40 fair, 0.41 – 0.60 moderate, 0.61 – 0.80 substantial, and 0.81 – 1.00 almost perfect²⁶. Differences between physician examinations and ratings were analyzed by linear and logistic regression. Figure 1 was created using Lowess regression. Data were analyzed using Stata (Stata, College Station, TX, USA) version 10.0. Statistical significance was set at the 0.05 level, confidence intervals were established at 95%, and all tests were 2-tailed.

RESULTS

The mean age of patients with RA was 59.1 (SD 13.6) years and 24.8% were men. The median duration of RA was 7.2 years, and 16.6% had RA for 2 years or less.

Table 1 shows percentages, means, and percentage missing data for a series of remission, MDA, and disease activity measures. Missing data were primarily determined by missing ESR values (46.8%), and this in turn was responsible for the inability to collect complete data for the DAS28, where the missing data level was 48.8%. According to ARCK clinic physicians, missing ESR data was caused by failure of primary care physicians, insurers, and health maintenance organizations to authorize or provide the ESR. The CDAI, which primarily requires physician data (3 items) and patient data (1 item), was missing in only 6.6%, the MD global remission was missing in 3.2%, and the PAS (all patient data) was missing in 5.1%.




Figure 1. Plot of DAS28 values against CDAI values (n = 435). The line is determined by Lowess regression. Circles below the horizontal line at 2.6 represent patients in DAS28 remission. Circles to the left of the vertical line at 2.8 represent patients in CDAI remission. Kappa for the DAS28 and CDAI scales was fair, 0.253²⁶.

Table 1. Remission, minimal disease activity, and clinical variables in 849 patients with RA.

Variable	n	All Data		Complete Data (n = 408)		
		% Missing	%*	Mean	Median	
Remission indices						
DAS28 ≤ 2.6	435	48.8	28.5		28.2	
CDAI ≤ 2.8	795	6.6	6.5		6.9	
CDAI ≤ 3	795	6.6	8.1		8.8	
MD global ≤ 1	816	4.9	12.5		14.5	
PAS-II ≤ 1.25	822	3.2	13.7		13.5	
Swollen, tender joints = 0	847	1.4	23.7		24.3	
Swollen, tender joints = 0, ESR < 10	453	46.8	9.5		8.1	
Minimal disease activity						
DAS28 criteria (DAS28 ≤ 2.85)	435	48.8	34.7		34.3	
Core criteria	424	50.1	26.9		26.0	
PAS-II ≤ 2.2	822	3.2	26.8		25.5	
Clinical variables						
	n	% Missing	Mean	Median	Mean	Median
DAS28 score (0–8.1)	435	48.8	3.3	3.2	3.4	3.2
CDAI (0–76)	795	6.6	13.4	10.5	12.1	9.5
PAS-II (0–10)	822	3.2	3.9	3.7	3.8	3.6
ESR, mm/h	453	46.8	23.1	17.0	23.6	18.0
MD 28 swollen joint count (0–28)	847	1.4	3.1	1.0	2.2	1.0
MD 28 tender joint count (0–28)	847	1.4	2.8	1.0	2.6	1.0
MD global (0–10)	816	4.9	3.5	3.0	3.4	3.0
Pain (0–10)	849	0.0	4.4	4.5	4.4	4.3
Global severity (0–10)	847	0.5	3.9	3.5	3.9	3.5
HAQ-II (0–3)	829	2.7	1.0	0.9	0.9	0.9

* Percentage positive excluding missing observations. DAS: Disease Activity Score; CDAI: Clinical Disease Activity Index; PAS: Patient Activity Scale; ESR: erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire.

With respect to remission, prevalence was quite different depending on the index examined (Table 1). DAS28 remission occurred in 28.5%, PAS-II remission in 13.7%, MD remission in 12.5%, and CDAI remission in 6.5%. When a cutoff of 3.0 was used (to adjust for slight scale differences) for CDAI, the remission proportion was 8.1%. MDA was 26.9% with Core criteria, 34.7% with DAS-28 criteria, and 26.8% with PAS-II criteria. There was little difference in prevalences for remission and MDA for patients with complete or incomplete data (Table 1).

We next investigated agreement among remission scales (Table 2, Figure 1). Agreement between most established

scales was fair (kappa 0.2–0.4), but was slightly better (moderate) for CDAI and MD global remission. Similar prevalences, therefore, do not mean the same patients are in remission or MDA. Although the kappa for agreement between DAS28 remission and CDAI remission was only 0.253, the Pearson correlation between DAS28 and CDAI as full scales was 0.826.

We further explored prevalence differences for the DAS28 (28.5%) and CDAI (6.5%) by examining the characteristics of patients in DAS28 remission but not in CDAI remission (lower right quadrant of Figure 1) in Figure 2 and by examining the characteristics of patients in CDAI remis-

Table 2. Kappa scores for paired remission categories

	DAS28 Remission (DAS28 ≤ 2.6)	Swollen, Tender Joints = 0	PAS-II Remission (PAS ≤ 1.25)	MD Remission (MD global ≤ 1)	CDAI Remission
Swollen, tender joints = 0	0.330				
PAS-II remission (PAS ≤ 1.25)	0.252	0.089			
MD remission (MD global ≤ 1)	0.318	0.428	0.286		
CDAI remission	0.253	0.321	0.404	0.506	
Swollen tender joints = 0, ESR < 10	0.366	0.431	0.115	0.297	0.345

DAS28: Disease Activity Score 28 joint count; PAS: Patient Activity Scale; CDAI: Clinical Disease Activity Index; ESR: erythrocyte sedimentation rate.




Figure 2. Histograms of CDAI remission variables in patients who are DAS28 remission-positive and CDAI remission-negative (n = 100).

sion (Figure 3) regardless of DAS28 score. Many patients in DAS28 but not CDAI remission have high patient global scores and more than minimal MD global scores, and some patients have high joint count scores (Figure 2). By contrast, CDAI remission patients have generally low scores for all measures (Figure 3).

To obtain a clearer sense of the relation between physician rating of disease activity and the DAS28 and CDAI scale, we performed logistic regression in 2 steps. First, we regressed MD remission (MD global ≤ 1) on DAS28 remission and CDAI remission. The odds ratio (OR) for DAS28 remission was 4.1 (95% CI 2.1–8.0) and the OR for CDAI remission was 31.6 (95% CI 10.0–100.2); the OR for the difference between these remission scores was 7.7 (95% CI 1.9–32.1). We also divided patients into 4 groups and determined the OR for the association of MD remission: no remission by any criteria (reference group); DAS28 remission but not CDAI remission, OR 4.2 (95% CI 2.1–8.6); CDAI remission but not DAS28 remission, OR 49.1 (95% CI 4.8–497.0); and remission by both criteria, OR 114.5 (95% CI 31.0–422.1). Although stronger associations with CDAI were to be expected because CDAI contains physician global, these results have important implications, given that the physician is the ultimate arbiter of disease activity in the setting of patient care.

We also studied whether differences between examining physician's evaluations might alter CDAI and DAS28 results. In this model we controlled for severity by including age, sex, patient global, patient pain, ESR, and RA duration as covariates. We then regressed separately swollen joint

counts, tender joint counts, and physician global on individual examining physicians and the covariates noted above. Individual physicians differed in their assessments of global severity ($p < 0.001$), tender joint counts ($p = 0.023$), and swollen joint counts ($p < 0.001$). We also tested physician differences by additionally adding as covariates the 2 omitted variables to the model from the 3 physician variables (swollen joint counts, tender joint counts, and physician global). Statistical significance was maintained in all analyses. These data show that physicians in our study systematically differed from each other with respect to their results for swollen joint counts, tender joint counts, and physician global.

Finally, we noted that use of biologics was not associated with more than minor differences in remission and MDA percentages for the key variables, DAS28, CDAI, physician's global, and PAS-II measures (Table 3).

DISCUSSION

One of the important objectives of our study was to examine the utility of the study measures in clinical practice. The DAS28 is a widely used and well documented scale. However, our data show that it was possible to obtain DAS28 scores in fewer than 50% of patients because of issues involving non-allowance of the test by referring primary care physicians and insurers, as reported by ARCK clinic physicians. Although rheumatology experts might decry this result, it can be observed that a person with complete data (ESR, in particular) did not seem to have other scores that were different from those with incomplete data.




Figure 3. CDAI remission variables in patients who are CDAI remission-positive (n = 28).

Table 3. Patients satisfying remission and MDA criteria according to biologic treatment status.

Variable	Remission (n), No Biologics (n = 488) n (%)	Remission (n), Biologics (n = 378) n (%)
Remission indices		
DAS28 remission ≤ 2.6	29.5 (261)	27.0 (174)
CDAI remission ≤ 2.8	7.5 (442)	5.4 (353)
MD remission (MD global ≤ 1)	12.9 (450)	12.0 (366)
PAS-II remission (PAS-II ≤ 1.25)	13.3 (459)	14.3 (363)
Swollen, tender joints = 0	27.1 (476)	19.4 (371)
Swollen, tender joints = 0, ESR < 10	29.5 (261)	27.0 (174)
Minimal disease activity (MDA)		
MDA, DAS28 criteria (DAS ≤ 2.85)	34.9 (261)	34.5 (174)
MDA, Core criteria	28.0 (250)	25.3 (174)
PAS-II (MDA ≤ 2.2)	25.9 (459)	27.8 (363)

DAS: Disease Activity Score; CDAI: Clinical Disease Activity Index; PAS: Patient Activity Scale; ESR: erythrocyte sedimentation rate.

It might be argued, further, that ESR testing is not needed or not needed as frequently. Our data cannot answer such a question, but they do raise the issue.

The inability to obtain ESR tests or to obtain them in a timely fashion so they could be used for clinical decision-making was one of the reasons that the CDAI was developed. The CDAI, in our hands, was simple to calculate and easy to use. However, we found that the remission prevalence using the DAS28 was 3 to 4 times greater than with the

CDAI (Table 1, Figure 1). These results, CDAI remission prevalence of 6.5% to 8.1%, are different from those published by the CDAI developers, who found remission in 33.5% of patients with CDAI and 42.7% by DAS28, and led us to examine the issue further³. To do this we examined 2 external sources. First, we used the RAES database²⁷. RAES was an observational study in which 644 patients were evaluated by DAS28 and CDAI by 61 physicians. As shown in Figure 4, the same pattern of reduced CDAI remission compared with DAS28 remission that we found in our study (Figure 1) was noted in the RAES database, and the remission prevalence was 7.8%. We also examined the results of the CDAI and DAS28 tests in more than 5,000 patients in Europe who participated in the QuestRA project and a separate cohort of over 800 US veterans with RA participating in the VARA Registry²⁸, and found the same pattern (personal communication from Tuulikki Sokka, MD, and Ted R. Mikuls, MD, MSPH, respectively; manuscripts in preparation).

Figures 2 and 3 provide insight into the remission differences of the CDAI and DAS28 scales. Many patients satisfying DAS28 remission criteria but not CDAI remission had high patient global scores and more than minimal MD global scores, and some patients have high joint count scores (Figure 2). By the nature of the CDAI definition, CDAI remission patients generally had low scores for all of the incorporated measures (Figure 3). In addition, there was greater agreement between physician global (and physician remission) with the CDAI compared with the DAS28,




Figure 4. Plot of DAS28 values against CDAI values in RAES database (n = 644). The line is determined by Lowess regression. Circles below the horizontal line at 2.6 represent patients in DAS28 remission. Circles to the left of the vertical line at 2.8 represent patients in CDAI remission.

although that was to be expected given that the physician global is part of the CDAI scale. The more stringent CDAI criteria had been noted previously by the CDAI authors^{3,6}, who found 33.5% of patients in remission by CDAI and 42.7% by DAS28 in a clinical practice setting³. Their prevalence for CDAI remission was 3 to 4 times greater than in our study and the RAES database.

The remission percentages shown in Table 1 for a series of different possible scales illustrate the problem of remission ascertainment when remission depends strongly on the remission definition. We note with interest that the remission percentage based on the physician's global (12.5%) is closer to the CDAI (6.5%) or the CDAI at a cutpoint of 3.0 (8.1%) than with the DAS28 (28.5%). Finnish investigators have also reported that the DAS28 remission cutoff may be too high⁸. Using the American College of Rheumatology preliminary criteria for remission¹⁵, they indicated that the best cutpoint for the DAS28 was 2.32. However, they noted that even with that cutpoint, a "substantial proportion of patients below the DAS28 cut off point for remission have tender or swollen joints, or both. DAS28 may not be an appropriate tool for assessment of remission in RA." A similar residua of active joints for patients in DAS28 remission was noted by the CDAI developers³. In our study, using a DAS28 cutpoint of 2.32, 20.3% of patients with RA met that criterion. Both the DAS28 and CDAI criteria also run up against the problem that they do not include the hips and feet, thereby potentially missing evidence of RA activity and misclassifying remission.

Therefore, there are problems with any set of current remission criteria, and this can be further illustrated with clinic data. If a physician determines that a patient is in remission, but that patient has a high tender joint count (for example, 3 tender joints for the CDAI) or a high ESR for reasons that are not related to RA activity, that patient cannot be designated as being in remission when criteria, but not clinical judgment, are used. This discrepancy, which also can go in the other direction, illustrates the differences between criteria that can be used in studies of groups of patients and criteria that are appropriate and useful for the single patient in clinical practice.

In addition to the group versus individual patient difficulty, Altman and Royston indicate that in dichotomizing continuous states "...one may seriously underestimate the extent of variation in outcome between groups, such as the risk of some event, and considerable variability may be subsumed within each group. Individuals close to but on opposite sides of the cutpoint are characterised as being very different rather than very similar"²⁹.

Additional problems with using measures such as the DAS28 and CDAI in the clinic relate to poor reliability. In our study, the 4 physicians differed in their assessments of joint swelling and tenderness and in physician global. It is known that these measures have poor reliabilities (< 0.80),

and the DAS has a reliability around 0.80^{22,30,31}. From reliability we can estimate the minimal detectable change (MDC; also called the reliable change or the smallest real difference)³²

$$\text{MDC} = \text{SEM} \times 1.96 * \sqrt{2}$$

$$\text{where SEM} = \text{SD} * \sqrt{1 - \text{reliability}}$$

The consequence of this is that, given 2 measurements in an individual patient, we can only say with confidence that differences between 2 assessments that are equal to or exceed ~2.0 for DAS28 are significant. The reason that the necessary differences are so great is that the uncertainty (reliability estimate) is applied not to the change score but to each of the 2 test measurements³³.

Another approach to RA activity is found in the MDA method. This method avoids the large differences between measures that might be seen because of examination differences at the margin of remission. The MDA for DAS was 34.7%, for the Core measures was 26.9%, and for the PAS-II was 26.8%, in general agreement with each other. We have not attempted to define MDA for CDAI.

While we have indicated that the CDAI is more likely to be collected than the DAS28 because of problems obtaining the ESR, it should not be concluded that the CDAI is optimal for clinical practice. The physicians in our study were highly motivated with respect to joint counts, and were provided with ongoing feedback by the NDB quality control staff. It is likely that the percentage of missing joint counts or other physician data will be much greater in actual practice. One potential solution to this problem is to use patient data, since their missing proportion is likely to be consistently low. However, the correlation between patient and physician data is only fair, with kappas between 0.252 and 0.402. It should also be noted that the difficulty obtaining ESR noted in our study might not be the case in other settings.

If one is going to collect physician data, however, the CDAI is one of the simplest and most intuitive measures available, and it would allow complete data collection among the patients in our study. We would also observe that the addition of the HAQ-II and a pain scale would allow complete assessment of both patient and physician data. Clinicians using such data would have full documentation of their patients' courses. For physicians who do not want to do formal joint examination, the physician global and the components of PAS-II allow rapid assessment. The physician global is performed by every physician, although not necessarily written down, but it is easy enough to do so.

The results of our study, showing wide differences in remission percentages, indicate a need for a general consensus on remission criteria definition. They also indicate the hazard of blindly using remission criteria in the clinic (Figures 1, 4). Use of CDAI scores on a continuous scale as

a guide, combined with the experienced clinician's judgment, may be an appropriate path to assessing remission in the clinic³⁴.

The prevalence of remission differs strikingly according to definition and scales. The DAS28 was available in < 50% because of incompletely available ESR values, suggesting the CDAI might be more clinically useful. However, additional studies are required to determine appropriate levels for disease activity and remission. The physician's determination of remission, considering all available evidence, may be the best approach to remission in the clinic. However, even when patients are similar, examination differences may lead to variable results.

ACKNOWLEDGMENT

We thank Dr. Tuulikki Sokka for making her QuestRA data available for our review, and for her thoughtful and very helpful comments on the manuscript.

REFERENCES

1. Steinbrocker O, Blazer A. A therapeutic score card for rheumatoid arthritis: A standardized method of appraising results of treatment. *N Engl J Med* 1946;235:501-6.
2. Khanna D, Oh M, Furst DE, et al. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. *Arthritis Rheum* 2007;57:440-7.
3. Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS. Assessing remission in clinical practice. *Rheumatology Oxford* 2007;46:975-9.
4. Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. *Arthritis Rheum* 2007;57:935-42.
5. Landewe R, van der Heijde D, van der Linden S, Boers M. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. *Ann Rheum Dis* 2006;65:637-41.
6. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. *Arthritis Rheum* 2005;52:2625-36.
7. Makinen H, Kautiainen H, Hannonen P, Sokka T. Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria: a 5-year followup study. *J Rheumatol* 2005;32:796-800.
8. Makinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? *Ann Rheum Dis* 2005;64:1410-3.
9. van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. *Ann Rheum Dis* 2005;64:1582-7.
10. Fransen J, Creemers MC, van Riel PL. Remission in rheumatoid arthritis: agreement of the Disease Activity Score (DAS28) with the ARA preliminary remission criteria. *Rheumatology Oxford* 2004;43:1252-5.
11. Paulus HE. Defining remission in rheumatoid arthritis: what is it? Does it matter? *J Rheumatol* 2004;31:1-4.
12. Svensson B, Schaufelberger C, Telemann A, Theander A. Remission and response to early treatment of RA assessed by the Disease Activity Score. *Rheumatology Oxford* 2000;39:1031-6.
13. Stucki G. Predicting and deciding on remission in rheumatoid arthritis. *Br J Rheumatol* 1996;35:1039-40.
14. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. *J Rheumatol* 1985;12:245-52.
15. Pinals RS, Baum J, Bland J, et al. Preliminary criteria for clinical remission in rheumatoid arthritis. *Arthritis Rheum* 1981;24:1308-15.
16. Short CL. Long remissions in rheumatoid arthritis. *Medicine* 1964;43:401-6.
17. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum* 1980;23:137-45.
18. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies and clinical trials: The Patient Activity Scale (PAS/PAS-II). *J Rheumatol* 2005;32:2410-5.
19. Wells GA, Boers M, Shea B, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. *J Rheumatol* 2005;32:2016-24.
20. Wolfe F, Pincus T, Tennant A. HAQ-II: Application of modern item response theory to the design of an improved HAQ questionnaire [abstract]. *Ann Rheum Dis* 2002;61:190.
21. Wolfe F, Michaud K. A brief introduction to the National Data Bank for Rheumatic Diseases. *Clin Exp Rheumatol* 2005; 23:S168-71.
22. van Riel PL. DAS-SCORE.NL. Available from: <http://www.das-score.nl/www.das-score.nl/>. Accessed March 4, 2008.
23. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. *Arthritis Rheum* 1993;36:729-40.
24. Felson DT. Choosing a core set of disease activity measures for rheumatoid arthritis clinical trials. *J Rheumatol* 1993;20:531-4.
25. Wolfe F, Michaud K, Pincus T. Development and validation of the Health Assessment Questionnaire II: a revised version of the Health Assessment Questionnaire. *Arthritis Rheum* 2004;50:3296-305.
26. Fleiss JL. *Statistical methods for rates and proportions*. New York: John Wiley & Sons; 1981.
27. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. *Arthritis Rheum* 2005;52:3873-9.
28. Mikuls TR, Kazi S, Cipher D, et al. The association of race and ethnicity with disease expression in male US veterans with rheumatoid arthritis. *J Rheumatol* 2007;34:1480-4.
29. Altman DG, Royston P. The cost of dichotomising continuous variables. *BMJ* 2006;332:1080.
30. Lassere MN, van der Heijde D, Johnson KR, Boers M, Edmonds J. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. *J Rheumatol* 2001; 28:892-903.
31. Kvien TK, Uhlig T, Mowinckel P, Pincus T. Test-retest reliability of DAS-28 and other standard assessment tools in patients with rheumatoid arthritis: defining cut-offs for changes exceeding the measurement error. *Ann Rheum Dis* 2007;64:213.
32. Schmitt JS, Di Fabio RP. Reliable change and minimum important difference (MID) proportions facilitated group responsiveness comparisons using individual threshold criteria. *J Clin Epidemiol* 2004;57:1008-18.
33. Wolfe F. The effective use of questionnaires in clinical practice. *Arthritis Rheum* 2007;57:705-6.
34. van Riel PL, Fransen J. To be in remission or not: is that the question? *Ann Rheum Dis* 2005;64:1389-90.